Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the predominant cause of familial Parkinson's disease. We previously reported that parkin-/- mice exhibit nigrostriatal deficits in the absence of nigral degeneration. Parkin has been shown to function as an E3 ubiquitin ligase. Loss of parkin function, therefore, has been hypothesized to cause nigral degeneration via an aberrant accumulation of its substrates. Here we employed a proteomic approach to determine whether loss of parkin function results in alterations in abundance and/or modification of proteins in the ventral midbrain of parkin-/- mice. Two-dimensional gel electrophoresis followed by mass spectrometry revealed decreased abundance of a number of proteins involved in mitochondrial function or oxidative stress. Consistent with reductions in several subunits of complexes I and IV, functional assays showed reductions in respiratory capacity of striatal mitochondria isolated from parkin-/- mice. Electron microscopic analysis revealed no gross morphological abnormalities in striatal mitochondria of parkin-/- mice. In addition, parkin-/- mice showed a delayed rate of weight gain, suggesting broader metabolic abnormalities. Accompanying these deficits in mitochondrial function, parkin-/- mice also exhibited decreased levels of proteins involved in protection from oxidative stress. Consistent with these findings, parkin-/- mice showed decreased serum antioxidant capacity and increased protein and lipid peroxidation. The combination of proteomic, genetic, and physiological analyses reveal an essential role for parkin in the regulation of mitochondrial function and provide the first direct evidence of mitochondrial dysfunction and oxidative damage in the absence of nigral degeneration in a genetic mouse model of Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, mitophagy deficiency favored by ablation of Prkn (Palacino et al, 2004; Pickrell et al, 2015) or Pink1 (Gautier et al, 2008) sensitizes mice to oxidative stress, while worsening neural damage when combined with mitochondrial dysfunction (mitochondrial DNA [mtDNA] mutator‐prkn/parkin‐KO mice) (Pickrell et al, 2015).”
From Autophagy in major human diseases (2021) · cites this paper as Palacino et al, 2004
In the citing paper
“Both Pink1 and Parkin knockout mice exhibit increased ROS levels and mitochondrial dysfunction (43, 44), and persistent increased ROS is one of the important factors in accelerating cellular senescence (42, 45).”
From Impaired mitophagy leads to cigarette smoke stress‐induced cellular senescence: implications for chronic obstructive pulmonary disease (2015) · cites this paper as [43]
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., & Pallanck, L. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737556100 · Cited by 1,203
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Research works printed but not linked: 5
- Jenner, 1996, Neurology, 47, 5161
- Koller, 1986, Neurology, 36
- Darios, 2003, Hum. Mol. Genet., 12, 517, 10.1093/hmg/ddg044 · doi:10.1093/hmg/ddg044 · Paper page
- Klose, 1999, Methods Mol. Biol., 112, 67
- Dubin, 1989, Mol. Cell. Biol., 9, 1083
Cited by
Items 601–700 of 1,000
Pallanck, L. J., & Greenamyre, J. T. (2006) · Nature · doi:10.1038/4411058a · Cited by 31
AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease
Haskin, J., Szargel, R., Shani, V., Mekies, L. N., Rott, R., Lim, G. G. Y., Lim, K.-L., Bandopadhyay, R., Wolosker, H., & Engelender, S. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt058 · Cited by 30
Mao, L., Zabel, C., Herrmann, M., Nolden, T., Mertes, F., Magnol, L., Chabert, C., Hartl, D., Hérault, Y., Delabar, J. M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001218 · Cited by 30
Self-citationElkharaz, J., Ugun‐Klusek, A., Constantin‐Teodosiu, D., Lawler, K., Mayer, R. J., Billett, E. E., Lowe, J. S., & Bedford, L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.07.002 · Cited by 30
Mitophagy in Neurodegeneration: An Opportunity for Therapy?
Santos, R. X., Correia, S. C., Carvalho, C., Cardoso, S., Santos, M. S., & Moreira, P. I. (2011) · Current Drug Targets · doi:10.2174/138945011795528813 · Cited by 30
Mitochondrial dysfunction in Parkinson’s disease
Бунеева, О. А., & Medvedev, A. E. (2011) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750811040032 · Cited by 30
Su, Y., Duan, J., Ying, Z., Hou, Y., Zhang, Y., Wang, R., & Deng, Y. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.045 · Cited by 30
Terriente-Félix, A., Wilson, E. L., & Whitworth, A. J. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008844 · Cited by 30
HIF‐1α Ameliorates Diabetic Neuropathic Pain via Parkin‐Mediated Mitophagy in a Mouse Model
He, J., Qin, Z., Chen, X., He, W., Li, D., Zhang, L., Le, Y., Xiong, Q., Zhang, B., & Wang, H. (2022) · BioMed Research International · doi:10.1155/2022/5274375 · Cited by 29
Algarzae, N. K., Hebron, M. L., Miessau, M., & Moussa, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.08.057 · Cited by 29
Phenotypic variability of parkin mutations in single kindred
Koentjoro, B., Park, J., Ha, A. D., & Sue, C. M. (2012) · Movement Disorders · doi:10.1002/mds.25041 · Cited by 28
Parkin Modulates Gene Expression in Control and Ceramide-Treated PC12 Cells
Unschuld, P. G., Dächsel, J. C., Darios, F. D., Kohlmann, A., Casademunt, E., Lehmann‐Horn, K., Dichgans, M., Ruberg, M., Brice, A., Gasser, T., et al. (2006) · Molecular Biology Reports · doi:10.1007/s11033-005-3961-5 · Cited by 28
Gene therapy: a viable therapeutic strategy for Parkinson’s disease?
Berry, A. L., & Foltynie, T. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5796-9 · Cited by 28
Dung, V. M., & Thảo, Đ. T. P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0529-0_4 · Cited by 28
Lippolis, R., Siciliano, R. A., Pacelli, C., Ferretta, A., Mazzeo, M. F., Scacco, S., Papa, F., Gaballo, A., Dell’Aquila, C., Mari, M. D., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.06.015 · Cited by 28
The relationship between parkin and protein aggregation in neurodegenerative diseases
Khandelwal, P. J., & Moussa, C. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00015 · Cited by 27
Park, B., Yang, J.-Y., Yun, N., Choe, K., Jin, B. K., & Oh, Y. J. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.04.005 · Cited by 27
Moon, H. E., Yoon, S. H., Hur, Y. S., Park, H. W., Ha, J. Y., Kim, K., Shim, J. H., Yoo, S. H., Son, J. H., Paek, S. L., et al. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.4.283 · Cited by 27
Neurodegenerative diseases and cancer: sharing common mechanisms in complex interactions
Rojas, N. G., Cesarini, M., Etcheverry, J. L., Prat, G. A. D., Arciuch, V. G. A., & Gatto, E. M. (2020) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2020.01.3 · Cited by 27
Mitochondrial and Organellar Crosstalk in Parkinson’s Disease
Ray, B., Bhat, A., Mahalakshmi, A. M., Tuladhar, S., Bishir, M., Mohan, S. K., Veeraraghavan, V. P., Chandra, R., Essa, M. M., Chidambaram, S. B., et al. (2021) · ASN NEURO · doi:10.1177/17590914211028364 · Cited by 27
Role of Mitochondrial Dysfunction in Parkinson???s Disease: Implications for Treatment
Ramsey, C. P., & Giasson, B. I. (2007) · Drugs & Aging · doi:10.2165/00002512-200724020-00002 · Cited by 27
Familial Occurrence of Dementia and Parkinsonism
Kurz, M. W., Schlitter, A. M., Larsen, J. P., Ballard, C. G., & Aarsland, D. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095159 · Cited by 27
Dayan, S., O’Keefe, L. V., Choo, A., & Richards, R. I. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22078 · Cited by 26
Immune cell metabolic dysfunction in Parkinson’s disease
Mark, J. R., & Tansey, M. G. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00827-y · Cited by 26
Mitochondria As A Target For Early Detection and Diagnosis of Cancer
Kagan, J., & Srivastava, S. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295477 · Cited by 26
Cossu, D., Yokoyama, K., Sato, S., Noda, S., Sechi, L. A., & Hattori, N. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577694 · Cited by 26
Hennis, M. R., Seamans, K. W., Marvin, M. A., Casey, B. H., & Goldberg, M. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084894 · Cited by 26
Self-citationYokota, M., Kakuta, S., Shiga, T., Ishikawa, K., Okano, H., Hattori, N., Akamatsu, W., & Koike, M. (2021) · Molecular Brain · doi:10.1186/s13041-021-00771-0 · Cited by 26
GPA protects the nigrostriatal dopamine system by enhancing mitochondrial function
Horváth, T. L., Erion, D. M., Elsworth, J. D., Roth, R. H., Shulman, G. I., & Andrews, Z. B. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.005 · Cited by 25
Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity
Solano, R. M., Menéndez, J., Casarejos, M. J., Rodríguez‐Navarro, J. A., de Yébenes, J. G., & Mena, M. A. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.027 · Cited by 25
OXPHOS toxicogenomics and Parkinson's disease
López‐Gallardo, E., Iceta, R., Iglesias, E., Montoya, J., & Ruiz‐Pesini, E. (2011) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2011.06.004 · Cited by 25
Benetti, F., Gustincich, S., & Legname, G. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.659661 · Cited by 25
Chithra, Y., Dey, G., Ghose, V., Chandramohan, V., Gowthami, N., Vasudev, V., & Bharath, M. M. S. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03907-x · Cited by 25
Aguiar, A. S., Tristão, F. S. M., Amar, M., Chevarin, C., Lanfumey, L., Mongeau, R., Corti, O., Prediger, R. D., & Raisman‐Vozari, R. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9389-0 · Cited by 25
Protective Effects of Zonisamide Against Rotenone-Induced Neurotoxicity
Condello, S., Currò, M., Ferlazzo, N., Costa, G., Visalli, G., Caccamo, D., Pisani, L. R., Costa, C., Calabresi, P., Ientile, R., et al. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1181-2 · Cited by 25
Abeliovich, A. (2007) · Nature · doi:10.1038/448759a · Cited by 24
Zanon, A., Pramstaller, P. P., Hicks, A. A., & Pichler, I. (2018) · Parkinson s Disease · doi:10.1155/2018/8684906 · Cited by 24
Li, C., & Beal, M. F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508350102 · Cited by 25
Kim, K., & Sack, M. N. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc5d · Cited by 24
Dietary Macronutrient Management to Treat Mitochondrial Dysfunction in Parkinson’s Disease
Bajracharya, R., Youngson, N. A., & Ballard, J. W. O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081850 · Cited by 25
Neurodegenerative disorders: Dysregulation of a carefully maintained balance?
Swart, C., Haylett, W. L., Kinnear, C. J., Johnson, G., Bardien, S., & Loos, B. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.09.003 · Cited by 23
Mitochondria: Prospective Targets for Neuroprotection in Parkinson’s Disease
Yadav, A., Agarwal, S., Tiwari, S. K., & Chaturvedi, R. K. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140305224545 · Cited by 23
MacCormac, L. P., Muqit, M. M. K., Faulkes, D. J., Wood, N. W., & Latchman, D. S. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03659.x · Cited by 23
Mitochondrial Homeostasis Molecules: Regulation by a Trio of Recessive Parkinson’s Disease Genes
Han, J., Kim, J., & Son, J. H. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.4.345 · Cited by 23
Interplay between α-synuclein and parkin genes: Insights of Parkinson’s disease
Sharma, K., Chib, S., Gupta, A., Singh, R., & Chalotra, R. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09520-7 · Cited by 23
Coleman, C. R., Pallos, J., Arreola-Bustos, A., Wang, L., Raftery, D., Promislow, D., & Martin, I. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403450121 · Cited by 23
Proteomic studies associated with Parkinson’s disease
Kasap, M., Akpınar, G., & Kanlı, A. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1291344 · Cited by 24
Altered Hippocampal Synaptic Physiology in Aged Parkin-Deficient Mice
Hanson, J. E., Orr, A., & Madison, D. V. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8113-y · Cited by 23
Studies of Depression-Related States in Animal Models of Parkinsonism
Schintu, N., Zhang, X., & Svenningsson, P. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-12076 · Cited by 22
Brain Damage - Bridging Between Basic Research and Clinics
González-Quevedo, A. (2012) · InTech eBooks · doi:10.5772/2174 · Cited by 22
Chan, F., Lax, N. Z., Davies, C. H., Turnbull, D. M., & Cunningham, M. O. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.033 · Cited by 22
Disease-Toxicant Interactions in Parkinson’s Disease Neuropathology
Kwakye, G. F., McMinimy, R. A., & Aschner, M. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2052-4 · Cited by 22
The intertwined relationship between circadian dysfunction and Parkinson's disease
Duret, L. C., & Nagoshi, E. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.10.006 · Cited by 22
Regulation of Parkin expression as the key balance between neural survival and cancer cell death
Murillo-González, F. E., García-Aguilar, R., Vega, L., & Elizondo, G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114650 · Cited by 22
Ubiquitin-protein ligase parkin and its role in the development of Parkinson’s disease
Бунеева, О. А., & Medvedev, A. E. (2006) · Biochemistry (Moscow) · doi:10.1134/s0006297906080050 · Cited by 22
Tanzarella, P., Ferretta, A., Barile, S. N., Ancona, M., Rasmo, D. D., Signorile, A., Papa, S., Capitanio, N., Pacelli, C., & Cocco, T. (2019) · Cells · doi:10.3390/cells8030250 · Cited by 22
G93A SOD1 alters cell cycle in a cellular model of Amyotrophic Lateral Sclerosis
Cova, E., Ghiroldi, A., Guareschi, S., Mazzini, G., Gagliardi, S., Davin, A., Bianchi, M., Ceroni, M., & Cereda, C. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.05.016 · Cited by 22
Vekaria, H. J., Kalimon, O. J., Prajapati, P., Velmurugan, G. V., & Sullivan, P. G. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1378536 · Cited by 22
Mitochondrial proteomics as a selective tool for unraveling Parkinson’s disease pathogenesis
Pienaar, I. S., Dexter, D. T., & Burkhard, P. R. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.8 · Cited by 21
Parkinson's Disease: Genetics and Pathogenesis
Testa, C. M. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn063 · Cited by 21
Mitochondrial Phenotypes in Parkinson’s Diseases—A Focus on Human iPSC-Derived Dopaminergic Neurons
Heger, L. M., Wise, R. M., Hees, J. T., Harbauer, A. B., & Burbulla, L. F. (2021) · Cells · doi:10.3390/cells10123436 · Cited by 21
Vergara, D., Gaballo, A., Signorile, A., Ferretta, A., Tanzarella, P., Pacelli, C., Paola, M. D., Cocco, T., & Maffia, M. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2198243 · Cited by 21
Stable Isotope Labeling and Label-Free Proteomics of Drosophila parkin Null Mutants
Xun, Z., Kaufman, T. C., & Clemmer, D. E. (2009) · Journal of Proteome Research · doi:10.1021/pr9006238 · Cited by 21
Pathology of Neurodegenerative Diseases
Kim, Y. S., Kim, Y.-K., Hwang, O., & Dong, J. (2012) · InTech eBooks · doi:10.5772/38028 · Cited by 21
Auburger, G. W. J., & Kurz, A. (2011) · Aging · doi:10.18632/aging.100258 · Cited by 20
Kaur, I., Behl, T., Sehgal, A., Singh, S., Sharma, N., Aleya, L., & BUNGAU, S. G. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-14619-6 · Cited by 20
Neurodegenerative Diseases Associated with Mitochondrial DNA Mutations
Zhunina, O. A., Yabbarov, N. G., Grechko, A. V., Yet, S.-F., Sobenin, I. A., & Orekhov, A. N. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191122091320 · Cited by 19
The pathogenesis of Parkinson’s disease and crosstalk with other diseases
Liu, T., GUO, D., & Wei, J. (2024) · Biocell · doi:10.32604/biocell.2024.051518 · Cited by 19
The Genetics of Alzheimer’s Disease and Parkinson’s Disease
Bekris, L. M., Yu, C., Bird, T. D., & Tsuang, D. W. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_21 · Cited by 19
Parkinson’s disease research: adopting a more human perspective to accelerate advances
Marshall, L. J., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.010 · Cited by 19
Leathem, A., Simone, M., Dennis, J. M., & Witting, P. K. (2022) · Antioxidants · doi:10.3390/antiox11020257 · Cited by 19
How proteomics reveals potential biomarkers in brain diseases
Schmidt, O., Schulenborg, T., Meyer, H. E., Marcus, K., & Hamacher, M. (2005) · Expert Review of Proteomics · doi:10.1586/14789450.2.6.901 · Cited by 19
Literature-Related Discovery (LRD)
Kostoff, R. N., Block, J. A., Solka, J. L., Briggs, M. B., Rushenberg, R. L., Stump, J. A., Johnson, D., Lyons, T. J., & Wyatt, J. R. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada473438 · Cited by 19
Parkinson's disease – molecular mechanisms of disease
Eriksen, J. L., & Petrucelli, L. (2004) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2004.11.016 · Cited by 19
Tumor Suppressor WWOX Contributes to the Elimination of Tumorigenic Cells in Drosophila melanogaster
O’Keefe, L. V., Lee, C. S., Choo, A., & Richards, R. I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136356 · Cited by 19
Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells
Xie, H., Chang, M., Hu, X., Wang, D., Tian, M., Li, G., Jiang, H., Wang, Y., Dong, Z., Zhang, Y., et al. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0340-3 · Cited by 19
Costa, D. K., Huckestein, B. R., Edmunds, L. R., Petersen, M. C., Nasiri, A. R., Butrico, G. M., Abulizi, A., Harmon, D. B., Lu, C., Mantell, B. S., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00042.2016 · Cited by 19
Genetic Analysis ofPARK2andPINK1Genes in Brazilian Patients with Early-Onset Parkinson's Disease
Moura, K. C. V., Campos, M., de Rosso, A. L. Z., Nicaretta, D. H., Pereira, J. S., Silva, D. J., dos Santos, F. L., Rodrigues, F. D. C., Santos-Rebouças, C. B., & Pimentel, M. M. G. (2013) · Disease Markers · doi:10.1155/2013/597158 · Cited by 19
Gómez‐Pinilla, F., & Feng, C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3293-7_2 · Cited by 19
Rethinking energy in parkinsonian motor symptoms: a potential role for neural metabolic deficits
Amano, J., Kegelmeyer, D. A., & Hong, S. L. (2015) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00242 · Cited by 18
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Ribarič, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084358 · Cited by 18
Mitochondrial disfunction in Parkinson's disease
Бунеева, О. А., & Medvedev, A. E. (2011) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20115703246 · Cited by 18
Buhlman, L. M. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.06.008 · Cited by 18
Increasing autophagy does not affect neurogenic muscle atrophy
Pigna, E., Sanna, K., Coletti, D., Li, Z., Parlakian, A., Adamo, S., & Moresi, V. (2018) · European Journal of Translational Myology · doi:10.4081/ejtm.2018.7687 · Cited by 18
Mechanisms for sperm mitochondrial removal in embryos
de Melo, K. P., & Camargo, M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118916 · Cited by 18
Kaindl, A. M., Zabel, C., Stefovska, V. G., Lehnert, R., Sifringer, M., Klose, J., & Ikonomidou, C. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200600696 · Cited by 18
Self-citationEXPRESSION OF CONCERN: Mitophagy protects against statin‐mediated skeletal muscle toxicity
Ramesh, I., Campos, J. C., Lee, P., Song, Y., Hernandez, G., Sin, J., Tucker, K. C., Saadaeijahromi, H., Gurney, M., Ferreira, J. C. B., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900807rr · Cited by 17
Post-translational modification and mitochondrial function in Parkinson’s disease
Luo, S., Wang, D., & Zhang, Z. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1329554 · Cited by 17
Mitochondrial Regulation by PINK1-Parkin Signaling
Imai, Y. (2012) · ISRN Cell Biology · doi:10.5402/2012/926160 · Cited by 17
López, S., Buil, A., Souto, J. C., Casademont, J., Martínez-Pérez, Á., Almasy, L. A., & Soria, J. M. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.09.004 · Cited by 17
Darvish-Damavandi, M., Ho, H. K., & Kang, T. S. (2016) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2016.06.009 · Cited by 17
Characterization of Dopaminergic System in the Striatum of Young Adult Park2−/− Knockout Rats
Gemechu, J. M., SHARMA, A. K., Yu, D., Xie, Y., Merkel, O. M., & Moszczyńska, A. (2018) · Scientific Reports · doi:10.1038/s41598-017-18526-0 · Cited by 17
Glucocorticoid Regulates Parkin Expression in Mouse Frontal Cortex: Implications in Schizophrenia
Pandya, C. D., Crider, A., & Pillai, A. (2014) · Current Neuropharmacology · doi:10.2174/1570159x11666131120224950 · Cited by 17
Petruzzella, V., Sardanelli, A. M., Scacco, S., Panelli, D., Papa, F., Trentadue, R., & Papa, S. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_17 · Cited by 17
Kitada, T., Ardah, M. T., & Haque, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316734 · Cited by 17
Dong, M., Zhang, T., Liang, X., Cheng, X., Shi, F., Yuan, H., Zhang, F., Jiang, Q., & Wang, X. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149815 · Cited by 17
Circadian Rhythms and Energy Metabolism Reprogramming in Parkinson's Disease
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2019) · Current Issues in Molecular Biology · doi:10.21775/cimb.031.021 · Cited by 17
Wood‐Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. Y., Miljan, E., Keen, G., Stanyer, L., Hargreaves, I. P., Klupsch, K., Deas, E., et al. (2008) · PLoS ONE · doi:10.1371/annotation/17d5aaa1-c6d8-4aad-a9a4-56b2c1220c83 · Cited by 17
Rogers, D. A., & Schor, N. F. (2010) · Annals of Neurology · doi:10.1002/ana.21841 · Cited by 17
Ozgul, S., Kasap, M., Akpınar, G., Kanlı, A., Güzel, N., Karaosmanoğlu, K., Baykal, A. T., & İşeri, P. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.03.007 · Cited by 17
Metadata
- Authors
- Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Shen, Jie
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 279
- Issue
- 18
- Pages
- 18614-18622
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2140647923
- Cited by
- 995
- References
- 66
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 34 · 2023: 29 · 2022: 27 · 2021: 44 · 2020: 51 · 2019: 39 · 2018: 41 · 2017: 32 · 2016: 41 · 2015: 41 · 2014: 42 · 2013: 60 · 2012: 49
- FWCI
- 42.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6031 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- Parkin, Parkinson's disease, mitochondrial dysfunction, oxidative stress, E3 ubiquitin ligase, nigrostriatal pathway, complex I, cytochrome c oxidase, respiratory capacity, lipid peroxidation, protein peroxidation, serum antioxidant capacity, metabolic abnormalities
- MeSH terms
- Animals, Antioxidants, Basal Ganglia, Mitochondria, Oxidative Phosphorylation, Parkinson Disease, Protein Processing, Post-Translational, Weight Gain, Reactive Oxygen Species, Mice, Knockout, Oxidative Stress, Cell Respiration, Mitochondrial Proteins, Mitochondrial Diseases, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.